CN1964711A - 眼睛选择性药物及前体药物 - Google Patents
眼睛选择性药物及前体药物 Download PDFInfo
- Publication number
- CN1964711A CN1964711A CNA2005800168904A CN200580016890A CN1964711A CN 1964711 A CN1964711 A CN 1964711A CN A2005800168904 A CNA2005800168904 A CN A2005800168904A CN 200580016890 A CN200580016890 A CN 200580016890A CN 1964711 A CN1964711 A CN 1964711A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- alkyl
- branched
- straight
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (62)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57415704P | 2004-05-25 | 2004-05-25 | |
US60/574,157 | 2004-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1964711A true CN1964711A (zh) | 2007-05-16 |
Family
ID=35450641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800168904A Pending CN1964711A (zh) | 2004-05-25 | 2005-05-24 | 眼睛选择性药物及前体药物 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20070254950A1 (zh) |
EP (1) | EP1750693A4 (zh) |
JP (1) | JP2008500359A (zh) |
KR (1) | KR20070026654A (zh) |
CN (1) | CN1964711A (zh) |
AU (1) | AU2005247480A1 (zh) |
BR (1) | BRPI0511462A (zh) |
CA (1) | CA2565321A1 (zh) |
EA (1) | EA012668B1 (zh) |
IL (1) | IL179336A0 (zh) |
NZ (1) | NZ551379A (zh) |
WO (1) | WO2005115375A1 (zh) |
ZA (1) | ZA200610032B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108101870A (zh) * | 2017-12-15 | 2018-06-01 | 盐城师范学院 | 一种选择性治疗青光眼的活性成份及其相关盐的制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005247480A1 (en) * | 2004-05-25 | 2005-12-08 | Qlt Inc. | Oculoselective drugs and prodrugs |
JP5198827B2 (ja) * | 2007-10-23 | 2013-05-15 | 株式会社日本ハイポックス | 神経変性疾患治療薬 |
JP5671459B2 (ja) | 2008-08-01 | 2015-02-18 | アイ・セラピーズ・エル・エル・シー | 血管収縮組成物および使用方法 |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
CA2782872A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4195085A (en) | 1975-09-26 | 1980-03-25 | Merck & Co., Inc. | Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate |
ZA772899B (en) | 1976-05-17 | 1978-04-26 | Pfizer | 9-hydroxyhexahydrobenzol(c)quinolines and intermediates therefor |
US4260764A (en) * | 1976-12-22 | 1981-04-07 | Pfizer Inc. | 9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor |
US4228169A (en) * | 1979-06-26 | 1980-10-14 | Pfizer Inc. | 1,9-Dihydroxyoctahydrobenzo[c]quinolines and 1-hydroxyhexahydrobenzo[c]quinoline-9(8H)-ones as antiemetic agents |
US4309545A (en) * | 1980-07-28 | 1982-01-05 | Pfizer Inc. | Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof |
US4455317A (en) | 1981-06-23 | 1984-06-19 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
US4454154A (en) * | 1981-06-23 | 1984-06-12 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
US4402974A (en) | 1981-06-23 | 1983-09-06 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
US4517199A (en) | 1981-11-20 | 1985-05-14 | Alcon Laboratories, Inc. | Method for lowering intraocular pressure using phenylimino-imidazoles |
US4515800A (en) * | 1981-11-20 | 1985-05-07 | Icilio Cavero | Method of lowering intraocular pressure using phenylimino-imidazoles |
US4461904A (en) * | 1981-11-20 | 1984-07-24 | Alcon Laboratories, Inc. | 2-(Trisubstituted phenylimino)-imidazolines |
CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
US4897417A (en) | 1988-12-15 | 1990-01-30 | E. I. Du Pont De Nemours & Co. | Prodrugs of 3,4-hydroxy benzoyloxypropanolamines |
US4966914A (en) * | 1988-12-15 | 1990-10-30 | E. I. Du Pont De Nemours And Company | Oculoselective beta-blockers as antiglaucoma agents |
DE4201079C3 (de) | 1992-01-17 | 1997-09-11 | Gramer Eugen | Kombinationspräparate zur Augeninnendrucksenkung |
US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
US5466233A (en) * | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5536749A (en) * | 1994-10-13 | 1996-07-16 | Sl Pharmaceuticals, Inc. | Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents |
US5725493A (en) * | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5605906A (en) * | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
FR2773320B1 (fr) | 1998-01-05 | 2000-03-03 | Optisinvest | Dispositif pour le transfert intraoculaire de produits actifs par iontophorese |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
AU2005247480A1 (en) * | 2004-05-25 | 2005-12-08 | Qlt Inc. | Oculoselective drugs and prodrugs |
-
2005
- 2005-05-24 AU AU2005247480A patent/AU2005247480A1/en not_active Abandoned
- 2005-05-24 EP EP05753712A patent/EP1750693A4/en not_active Withdrawn
- 2005-05-24 EA EA200602174A patent/EA012668B1/ru not_active IP Right Cessation
- 2005-05-24 US US11/597,070 patent/US20070254950A1/en not_active Abandoned
- 2005-05-24 CA CA002565321A patent/CA2565321A1/en not_active Abandoned
- 2005-05-24 WO PCT/US2005/018350 patent/WO2005115375A1/en active Application Filing
- 2005-05-24 CN CNA2005800168904A patent/CN1964711A/zh active Pending
- 2005-05-24 NZ NZ551379A patent/NZ551379A/en unknown
- 2005-05-24 JP JP2007515296A patent/JP2008500359A/ja active Pending
- 2005-05-24 BR BRPI0511462-4A patent/BRPI0511462A/pt not_active IP Right Cessation
- 2005-05-24 KR KR1020067027321A patent/KR20070026654A/ko not_active Application Discontinuation
- 2005-05-24 ZA ZA200610032A patent/ZA200610032B/xx unknown
- 2005-05-24 US US11/136,625 patent/US7678829B2/en active Active
-
2006
- 2006-11-16 IL IL179336A patent/IL179336A0/en unknown
-
2010
- 2010-02-05 US US12/701,374 patent/US20100179218A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108101870A (zh) * | 2017-12-15 | 2018-06-01 | 盐城师范学院 | 一种选择性治疗青光眼的活性成份及其相关盐的制备方法 |
CN108101870B (zh) * | 2017-12-15 | 2020-03-06 | 盐城师范学院 | 一种选择性治疗青光眼的活性成份及其相关盐的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2005115375A1 (en) | 2005-12-08 |
JP2008500359A (ja) | 2008-01-10 |
CA2565321A1 (en) | 2005-12-08 |
ZA200610032B (en) | 2008-11-26 |
EA012668B1 (ru) | 2009-12-30 |
IL179336A0 (en) | 2007-03-08 |
EP1750693A4 (en) | 2010-06-02 |
EP1750693A1 (en) | 2007-02-14 |
US20070254950A1 (en) | 2007-11-01 |
AU2005247480A1 (en) | 2005-12-08 |
US7678829B2 (en) | 2010-03-16 |
EA200602174A1 (ru) | 2007-04-27 |
BRPI0511462A (pt) | 2007-12-26 |
US20060019955A1 (en) | 2006-01-26 |
US20100179218A1 (en) | 2010-07-15 |
NZ551379A (en) | 2010-11-26 |
KR20070026654A (ko) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1964711A (zh) | 眼睛选择性药物及前体药物 | |
US20200276179A1 (en) | Combination Therapy | |
JP2013531063A (ja) | 二官能基Rhoキナーゼ阻害化合物、組成物およびその使用 | |
JP2013532689A (ja) | プロドラッグ形態のキナーゼ阻害剤化合物を使用して眼疾患を治療する方法 | |
EP0771563B1 (en) | Use of 5-HT1A receptor ligands for the treatment of glaucoma | |
JP2004518612A (ja) | インドール誘導体を用いて眼圧を下降させる方法 | |
CA2237898A1 (en) | Combination therapy for treating glaucoma | |
US8653304B2 (en) | 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same | |
EP3107906B1 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
AU778148B2 (en) | 2-aminotetralin derivatives for the therapy of glaucoma | |
SK69699A3 (en) | 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists | |
JP6520019B2 (ja) | 新規スチルベン誘導体 | |
NZ237026A (en) | Topical pharmaceutical compositions comprising 6-n-butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenanthroline-2,8-dicarboxylic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: OLTRAR HOLDING COMPANY Free format text: FORMER OWNER: OTHERA PHARMACEUTICALS INC. Effective date: 20081121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20081121 Address after: Delaware Applicant after: Othera Holdings Inc. Address before: American Pennsylvania Applicant before: Othera Pharmaceuticals Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: QLT PHOTOTHERAPEUTICS INC. Free format text: FORMER OWNER: OTHERA HOLDINGS INC. Effective date: 20110107 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: DELAWARE STATE, USA TO: VANCOUVER, CANADA |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110107 Address after: Vancouver, Canada Applicant after: QLT Inc. Address before: Delaware Applicant before: Othera Holdings Inc. |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20070516 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |